Antigen News and Research

RSS

Nanovaccine boosts immunity in mice with gut microbiome-mediated metabolic syndrome

A new class of biomaterial developed by Cornell researchers for an infectious disease nanovaccine effectively boosted immunity in mice with metabolic disorders linked to gut bacteria - a population that shows resistance to traditional flu and polio vaccines.

29 Mar 2019

Tumor biomarker EpCAM shown to be promising target for cancer immunotherapy

Researchers have shown that cancer immunotherapy targeting the tumor biomarker epithelial cell adhesion molecule is safe and nontoxic in mice and can significantly delay tumor formation and growth.

28 Mar 2019

Heating tumors during CAR T-cell therapy can enhance treatment's success, study suggests

A preclinical study led by scientists at the UCLA Jonsson Comprehensive Cancer suggests that heating solid tumors during CAR T-cell therapy can enhance the treatment's success.

28 Mar 2019

FDA approves new oral treatment for men with certain forms of hypogonadism

The U.S. Food and Drug Administration today approved Jatenzo (testosterone undecanoate), an oral testosterone capsule to treat men with certain forms of hypogonadism.

27 Mar 2019

City of Hope exhibits current studies and data on cancer therapies at AACR

City of Hope, a world-renowned independent research and treatment center for cancer and diabetes, will showcase ongoing studies and data on chimeric antigen receptor T cell therapy, immunotherapy against solid tumors and more at the American Association for Cancer Research annual meeting from March 29 through April 3 in Atlanta.

22 Mar 2019

Merck to collaborate with GenScript for plasmid and virus manufacturing in China

Merck, a leading science and technology company, today announced the signing of a non-binding Memorandum of Understanding with Chinese biotech company GenScript for a strategic alliance focusing on plasmid and viral vector manufacturing.

From Merck 20 Mar 2019

Testosterone treatment lowers recurrence rates in low-risk prostate cancer patients

In the largest such study so far undertaken, US researchers have shown that testosterone replacement slows the recurrence of prostate cancer in low-risk patients.

18 Mar 2019

Long-awaited structure offers new insights into rejection of transplanted organs

Rejection of any kind is always hard to deal with, but when one's body rejects a precious organ transplant, the consequences can be devastating. Professor A. Vathsala, Co-director of the National University Centre for Organ Transplantation at the National University Hospital and Professor of Medicine, shared that between 30% to 40% of kidney transplants are lost over time to rejection.

15 Mar 2019

FIND launches new schistosomiasis program within neglected tropical diseases portfolio

The Foundation for Innovative New Diagnostics announced today the launch of a new schistosomiasis programme within its neglected tropical diseases portfolio.

14 Mar 2019

New risk model can predict survival of non-metastatic prostate cancer patients

A new risk model, easily accessible on a web interface, can predict the survival of non-metastatic prostate cancer patients, as well as the effect of different treatment approaches on survival.

13 Mar 2019

Researchers identify gene that increases risk of antibiotic reaction

Researchers at Vanderbilt University Medical Center and colleagues have identified a gene that increases the risk for a severe and potentially life-threatening reaction to the commonly prescribed antibiotic vancomycin.

11 Mar 2019

CMV airway infection enlarges spectrum of environmental allergens

Cytomegalovirus infection can convert a harmless, inhaled protein antigen into an allergen, according to a study published March 7 in the open-access journal PLOS Pathogens by Rafaela Holtappels from the University Medical Center of the Johannes Gutenberg-University Mainz, and colleagues.

8 Mar 2019

Mechanism through which bacteria attack the immune system discovered

A research team led by Prof. Dr. Winfried Römer and Dr. Elias Hobeika from the University of Freiburg and the University Medical Center in Ulm has discovered a mechanism with which bacteria activate white blood cells and attack an organism's immune system. The scientists recently published the results in the journal Science Signaling.

7 Mar 2019

CAR-T cell therapy could be on the horizon for patients with lupus

Researchers have developed a novel CAR-T cell therapy that can reduce B cell numbers known to cause the inflammatory responses in lupus.

7 Mar 2019

Discovery of protein, lipid connection could lead to new influenza therapies

The connection between an influenza virus surface protein and a host cell lipid has been discovered by researchers at the University of Maine and the National Institutes of Health. Confirmation of direct interaction between the protein and lipid could lead to new antiviral therapies.

6 Mar 2019

Researchers examine process of gut-based cells involved in long-term immunity

Only a few vaccines - for example, against polio and rotavirus - can be given orally. Most must be delivered by injection.

5 Mar 2019

Using TGS technology to make the perfect match even better for stem cell transplant recipients

At Anthony Nolan we save the lives of people with blood cancers and blood disorders that need a stem cell transplant.

4 Mar 2019

Researchers reveal promising biomarker for vascular disease relapse

Researchers at Okayama University report in the journal Arthritis & Rheumatology that monitoring a particular antigen can be used for predicting relapse of the vascular disease AAV.

28 Feb 2019

Killer T cells may explain inability of immune cells to destroy cancer tumors

Scientists at the University of Virginia School of Medicine have discovered a defect in immune cells known as "killer T cells" that explains their inability to destroy cancer tumors. The researchers believe that repairing this defect could make the cells much better cancer killers.

26 Feb 2019

Immunotherapeutic antibody therapy to kill cancer has now progressed to patient testing

Developed by researchers at the University of Turku in Finland, an immunotherapeutic antibody therapy re-educates macrophages to activate passivated cytotoxic T cells to kill cancer. The antibody therapy prevented the growth of tumors in several mouse models.

20 Feb 2019